A clinical trial is underway by the US based, Japanese owned firm Asubio for their SUN13837 molecule. This trial is for acute (new) cervical injuries. They are hoping for an incredible 2-level improvement in quadriplegic patients. The difference this would make is enormous. For example, instead of basic weak bicep only arm movement, a C5 quadriplegic might get full arm and hand function.
Skip back to main navigation